StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck koselugo (selumetinib — AstraZeneca NF1 alliance revenue) — Worldwide ($M) ($M)

Form 8-K Table 3 Footnote & Form 10-Q / 10-K Collaborative Arrangements Note

QuarterlyAnnual
Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
-100.0%
5 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
8
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKoselugo (selumetinib — AstraZeneca NF1 alliance revenue) — Worldwide ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20260-100.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026132+38.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202527-51.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202511-71.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2025Jun 30, 20255-86.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202595+150.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 202456+143.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202439+50.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 202437+48.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202438+65.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 202323+109.1%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 202326+160.0%Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 202325–Form 10-Q (filed 2024-08-05) ↗
Q1 2023Mar 31, 202323–Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 202211–Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 202210–Form 10-Q (filed 2023-11-03) ↗

Cite this data

StockData. (2026). Merck Koselugo (selumetinib — AstraZeneca NF1 alliance revenue) — Worldwide ($M) ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_koselugo

See every metric in the Merck KPI table. Data updated Oct 26, 2026.